Xeris Biopharma Entered into a Research Collaboration and Option Agreement with Horizon for XeriJect Formulation of Teprotumumab
- Xeris to receive an up front & is eligible to receive development milestones, regulatory & sales-based milestones along with royalties based on future sales, upon exercise of the commercial license option
- The collaboration enables Xeris to use its formulation technology platform, XeriJect to develop an ultra-concentrated, ready-to-use, SC inj. of teprotumumab, the first US FDA-approved therapy for thyroid eye disease. Horizon to get an option to license the Xeris technology
- Three of the company's products are currently on the market: Recorlev for endogenous Cushing's syndrome, Keveyis, the first US FDA-approved therapy for primary periodic paralysis & Gvoke, a ready-to-use liquid glucagon for sev. hypoglycemia
Ref: Businesswire | Image: Horizon
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.